Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/23/24
End: 05/31/26
Due: 05/31/27
Phase: N/A
Priority: Normal
Start: 09/01/23
End: 04/30/26
Due: 04/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease) | NCT07002398 | VeonGen Therapeutics GmbH | user2@example.com | None | 2024-12-23 | 2026-05-31 | 2027-05-31 | - | - | 2025-07-14 |
| Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene | NCT06291935 | VeonGen Therapeutics GmbH | user2@example.com | None | 2023-09-01 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |